Asia
Celltrion are down more than 5 percent after the company announced it received a warning letter from the FDA after the regulatory agency inspected a company drug manufacturing facility.
In addition, Ping An formed a strategic partnership with TytoCare to lead the company’s expansion into China, probably through Ping An’s Good Doctor mobile app.
ARMO BioSciences completed a $128M IPO in the US after raising capital from China VCs;
Despite some safety concerns such as severe diarrhea, the FDA approved Puma’s breast cancer drug Nerlynx in July 2017.
New kid on the block Tmunity just banked a series A funding round worth $100M.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
Last year, AmoyDx’s EGFR diagnostic was approved for use in the EU.
Clover Biopharma announced plans to build a biologic drug manufacturing facility in Changxing, Zhejiang Province.
Another experimental Alzheimer’s disease treatment has failed in a late-stage study.
This acquisition strategy is part of its two-pronged approach to growth, along with internal R&D.
PRESS RELEASES